Imunon

Imunon EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Imunon (IMNN) as of Oct 15, 2026 is -0.23. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -0.33 — a change of -30.88% (higher).

EV/FCF

-0.23

YoY

-30.88%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Imunon is 2025 -0.23 . EV/FCF (Enterprise Value to Free Cash Flow) of Imunon was 2024 -0.33 . It decreases by -30.88% higher compared to the previous year.

The Imunon EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
0.99 USD
Jan 1, 2019
-0.37 USD
Jan 1, 2020
-0.01 USD
Jan 1, 2021
1.92 USD
Jan 1, 2022
0.66 USD
Jan 1, 2023
0.16 USD
Jan 1, 2024
-0.33 USD
Jan 1, 2025
-0.23 USD
The Imunon EV/FCF history
YEAREV/FCFYoY
-0.23-30.88%
-0.33-315.74%
0.16-76.52%
0.66-65.56%
1.92-36,731.68%
-0.01-98.57%
-0.37-136.70%
0.99+26.52%
0.79-255.81%
-0.50-508.02%
0.12-83.08%
0.73—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Imunon Stock analysis

What does Imunon do? Imunon Inc is a clinical stage oncology drug company headquartered in Lawrenceville, New Jersey. The company has 31 full-time employees and went public on October 27, 1993. Imunon focuses on developing treatments that leverage the body's natural mechanisms for various diseases. It operates two platform technologies: the TheraPlas platform for immunotherapies and nucleic acid-based anti-cancer therapies, and the PLACCINE platform for nucleic acid vaccines targeting infectious diseases and cancer. The company's lead clinical program, IMNN-001, is a DNA-based immunotherapy designed for localized treatment of advanced ovarian cancer. IMNN-001 functions by prompting the body to generate cancer-fighting molecules like interleukin-12 and interferon gamma directly at the tumor site. Additionally, Imunon is conducting preclinical research on a nucleic acid vaccine candidate against the SARS-CoV-2 virus to validate its PLACCINE platform. The company's technologies rely on synthetic delivery systems for nucleic acids, avoiding viral vectors or devices. Imunon's website is https://imunon.com/ and it is listed under the ticker IMNN with ISIN US15117N7012. The company operates within the health care sector, specifically in biotechnology. Imunon is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Imunon stock

EV/FCF (Enterprise Value to Free Cash Flow) of Imunon is -0.23 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Imunon changed from -0.33 to -0.23, representing a -30.88% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Imunon since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Imunon with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Imunon

All Key Metrics — Imunon